Velleca Mark A. reported BDTX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001706847-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Jan 21, 2026

Published

Jan 23, 2026

Ingested by INSIDER

Nov 5, 04:21 UTC

Last re-read

Nov 5, 04:21 UTC

Extracted facts

Filer

Velleca Mark A.

Role

Director, PRESIDENT & CEO

Transaction

Grant or awardAs filed: “A”

Asset

Black Diamond Therapeutics, Inc. — Stock Option (Right to Buy)

Ticker

BDTX

Shares

600.0K

Price per share

$0

Execution date (reported)

Jan 21, 2026

Owned after transaction

600.0K shares

Days from execution to publication

2

What this establishes

Velleca Mark A. filed this Form 4 reporting a grant or award of BDTX on Jan 21, 2026. It became public on Jan 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, PRESIDENT & CEO

Velleca Mark A.cik:0001706847

Issuer

Black Diamond Therapeutics, Inc.cik:0001701541

Revision history · 0

No field has changed since this record was first ingested.